Hydroxyl Group-Targeted Conjugate and Its Self-Assembled Nanoparticle of Peptide Drug: Effect of Degree of Saturation of Fatty Acids and Modification of Physicochemical Properties

References

• Jagot-Lacoussiere L, Kotula E, Villoutreix BO, Bruzzoni-Giovanelli H, Poyet JL. A cell-penetrating peptide targeting AAC-11 specifically induces cancer cells death. Cancer Res. 2016;76(18):5479–5490. doi:10.1158/0008-5472.can-16-0302
   PubMed Web of Science ®Google Scholar
• Usmani SS, Bedi G, Samuel JS, et al. THPdb: database of FDA-approved peptide and protein therapeutics. PLoS One. 2017;12(7):e0181748. doi:10.1371/journal.pone.0181748
   PubMed Web of Science ®Google Scholar
• Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–2707. doi:10.1016/j.bmc.2017.06.052
   PubMed Web of Science ®Google Scholar
• Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist. 2000;5(2):162–168. doi:10.1634/theoncologist.5-2-162
   PubMedGoogle Scholar
• Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs. 1994;48(6):930–967. doi:10.2165/00003495-199448060-00008
   PubMed Web of Science ®Google Scholar
• Rosario DJ, Davey P, Green J, et al. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol. 2016;34(12):1601–1609. doi:10.1007/s00345-016-1818-2
   PubMed Web of Science ®Google Scholar
• Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur J Pharm Sci. 2006;27(2–3):143–149. doi:10.1016/j.ejps.2005.09.002
   PubMed Web of Science ®Google Scholar
• Gallagher JS, Missmer SA, Hornstein MD, Laufer MR, Gordon CM, DiVasta AD. Long-term effects of gonadotropin-releasing hormone agonists and add-back in adolescent endometriosis. J Pediatr Adolesc Gynecol. 2018;31(4):376–381. doi:10.1016/j.jpag.2018.03.004
   PubMed Web of Science ®Google Scholar
• Morales JO, Huang S, Williams RO 3rd, McConville JT. Films loaded with insulin-coated nanoparticles (ICNP) as potential platforms for peptide buccal delivery. Colloids Surf B Biointerfaces. 2014;122:38–45. doi:10.1016/j.colsurfb.2014.05.025
   PubMed Web of Science ®Google Scholar
• Nguyen OOT, Tran KD, Ha NT, Doan SM, Dinh TTH, Tran TH. Oral cavity: an open horizon for nanopharmaceuticals. J Pharm Invest. 2021;51(4):413–424. doi:10.1007/s40005-021-00530-2
   Web of Science ®Google Scholar
• Kim Y-C, Min KA, Jang D-J, et al. Practical approaches on the long-acting injections. J Pharm Invest. 2020;50(2):147–157. doi:10.1007/s40005-019-00452-0
   Web of Science ®Google Scholar
• Zheng Y, Qiu Y, Lu MF, Hoffman D, Reiland TL. Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. Int J Pharm. 1999;185(1):83–92. doi:10.1016/S0378-5173(99)00146-5
   PubMed Web of Science ®Google Scholar
• Haggag YA, Donia AA, Osman MA, El-Gizawy SA. Peptides as drug candidates: limitations and recent development perspectives. Biomed J. 2018;1:3.
   Google Scholar
• Haviy F, Fitzpatrick TD, Nichols CJ, et al. Stabilization of the N-terminal residues of luteinizing hormone-releasing hormone agonists and the effect on pharmacokinetics. J Med Chem. 1992;35(21):3890–3894. doi:10.1021/jm00099a017
   PubMed Web of Science ®Google Scholar
• Ochi M, Wan B, Bao Q, Burgess DJ. Influence of PLGA molecular weight distribution on leuprolide release from microspheres. Int J Pharm. 2021;599:120450. doi:10.1016/j.ijpharm.2021.120450
   PubMed Web of Science ®Google Scholar
• Sophocleous AM, Desai KG, Mazzara JM, et al. The nature of peptide interactions with acid end-group PLGAs and facile aqueous-based microencapsulation of therapeutic peptides. J Control Release. 2013;172(3):662–670. doi:10.1016/j.jconrel.2013.08.295
   PubMed Web of Science ®Google Scholar
• Fu M, Zhuang X, Zhang T, Guan Y, Meng Q, Zhang Y. PEGylated leuprolide with improved pharmacokinetic properties. Bioorg Med Chem. 2020;28(4):115306. doi:10.1016/j.bmc.2020.115306
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu MR, Wan HT. Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull. 2014;37(3):335–339. doi:10.1248/bpb.b13-00661
   PubMed Web of Science ®Google Scholar
• Han FY, Thurecht KJ, Whittaker AK, Smith MT. Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Front Pharmacol. 2016;7:185. doi:10.3389/fphar.2016.00185
   PubMed Web of Science ®Google Scholar
• Kim D, Park C, Meghani NM, et al. Utilization of a fattigation platform gelatin-oleic acid sodium salt conjugate as a novel solubilizing adjuvant for poorly water-soluble drugs via self-assembly and nanonization. Int J Pharm. 2020;575:118892. doi:10.1016/j.ijpharm.2019.118892
   PubMed Web of Science ®Google Scholar
• Park C, Meghani N, Amin H, et al. The roles of short and long chain fatty acids on physicochemical properties and improved cancer targeting of albumin-based fattigation-platform nanoparticles containing doxorubicin. Int J Pharm. 2019;564:124–135. doi:10.1016/j.ijpharm.2019.04.038
   PubMed Web of Science ®Google Scholar
• Amin HH, Meghani NM, Oh KT, Choi H, Lee B-J. A conjugation of stearic acid to apotransferrin, fattigation-platform, as a core to form self-assembled nanoparticles: encapsulation of a hydrophobic paclitaxel and receptor-driven cancer targeting. J Drug Deliv Sci Technol. 2017;41:222–230. doi:10.1016/j.jddst.2017.07.013
   Web of Science ®Google Scholar
• Park C, Baek N, Loebenberg R, Lee BJ. Importance of the fatty acid chain length on in vitro and in vivo anticancer activity of fattigation-platform albumin nanoparticles in human colorectal cancer xenograft mice model. J Control Release. 2020;324:55–68. doi:10.1016/j.jconrel.2020.05.001
   PubMed Web of Science ®Google Scholar
• Kanikkannan N, Kandimalla K, Lamba SS, Singh M. Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. Curr Med Chem. 2000;7(6):593–608. doi:10.2174/0929867003374840
   PubMed Web of Science ®Google Scholar
• Dhimitruka I, Santalucia J Jr. Investigation of the Yamaguchi esterification mechanism. Synthesis of a lux-s enzyme inhibitor using an improved esterification method. Org Lett. 2006;8(1):47–50. doi:10.1021/ol0524048
   PubMed Web of Science ®Google Scholar
• Bech EM, Pedersen SL, Jensen KJ. Chemical strategies for half-life extension of biopharmaceuticals: lipidation and its alternatives. ACS Med Chem Lett. 2018;9(7):577–580. doi:10.1021/acsmedchemlett.8b00226
   PubMed Web of Science ®Google Scholar
• Eskandari S, Guerin T, Toth I, Stephenson RJ. Recent advances in self-assembled peptides: implications for targeted drug delivery and vaccine engineering. Adv Drug Deliv Rev. 2017;110–111:169–187. doi:10.1016/j.addr.2016.06.013
   PubMed Web of Science ®Google Scholar
• Pérez-López A, Martín-Sabroso C, Torres-Suárez AI. Timeline of translational formulation technologies for cancer therapy: successes, failures, and lessons learned therefrom. Pharmaceutics. 2020;12(11). doi:10.3390/pharmaceutics12111028
   PubMed Web of Science ®Google Scholar
• Meghani NM, Amin HH, Park C, et al. Design and evaluation of clickable gelatin-oleic nanoparticles using fattigation-platform for cancer therapy. Int J Pharm. 2018;545(1–2):101–112. doi:10.1016/j.ijpharm.2018.04.047
   PubMed Web of Science ®Google Scholar
• Satapathy SR, Sahoo RN, Satapathy B, Immani R, Panigrahi L, Mallick S. Development and characterization of leuprolide acetate encapsulated PLGA microspheres for parenteral controlled release depot injection. Indian J Pharm Edu Res. 2021;55(1):107–116. doi:10.5530/ijper.55.1.14
   Web of Science ®Google Scholar
• Cao SJ, Xu S, Wang HM, et al. Nanoparticles: oral delivery for protein and peptide drugs. AAPS PharmSciTech. 2019;20(5):190. doi:10.1208/s12249-019-1325-z
   PubMed Web of Science ®Google Scholar
• Kim H, Song D, Ngo HV, et al. Modulation of the clinically accessible gelation time using glucono-d-lactone and pyridoxal 5’-phosphate for long-acting alginate in situ forming gel injectable. Carbohydr Polym. 2021;272:118453. doi:10.1016/j.carbpol.2021.118453
   PubMed Web of Science ®Google Scholar
• Hac-Wydro K, Wydro P. The influence of fatty acids on model cholesterol/phospholipid membranes. Chem Phys Lipids. 2007;150(1):66–81. doi:10.1016/j.chemphyslip.2007.06.213
   PubMed Web of Science ®Google Scholar
• Padula C, Pescina S, Nicoli S, Santi P. New insights on the mechanism of fatty acids as buccal permeation enhancers. Pharmaceutics. 2018;10(4). doi:10.3390/pharmaceutics10040201
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P, Mohammadi-Samani S. Potential of nanoparticles as permeation enhancers and targeted delivery options for skin: advantages and disadvantages. Drug Design Develop Ther. 2020;14:3271–3289. doi:10.2147/dddt.s264648
   PubMed Web of Science ®Google Scholar